BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34536193)

  • 1. A long noncoding RNA-microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas.
    Ghosal S; Zhu B; Huynh TT; Meuter L; Jha A; Talvacchio S; Knue M; Patel M; Prodanov T; Das S; Zeiger MA; Nilubol N; Shankavaram UT; Taieb D; Pacak K
    Endocrine; 2022 Jan; 75(1):244-253. PubMed ID: 34536193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker.
    Ghosal S; Das S; Pang Y; Gonzales MK; Huynh TT; Yang Y; Taieb D; Crona J; Shankavaram UT; Pacak K
    Int J Cancer; 2020 Apr; 146(8):2326-2335. PubMed ID: 31469413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
    Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
    Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
    Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NAD
    Pang Y; Lu Y; Caisova V; Liu Y; Bullova P; Huynh TT; Zhou Y; Yu D; Frysak Z; Hartmann I; Taïeb D; Pacak K; Yang C
    Clin Cancer Res; 2018 Jul; 24(14):3423-3432. PubMed ID: 29636359
    [No Abstract]   [Full Text] [Related]  

  • 6. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.
    de Cubas AA; Leandro-García LJ; Schiavi F; Mancikova V; Comino-Méndez I; Inglada-Pérez L; Perez-Martinez M; Ibarz N; Ximénez-Embún P; López-Jiménez E; Maliszewska A; Letón R; Gómez Graña A; Bernal C; Alvarez-Escolá C; Rodríguez-Antona C; Opocher G; Muñoz J; Megias D; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):477-93. PubMed ID: 23660872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis.
    Ghosal S; Hadrava Vanova K; Uher O; Das S; Patel M; Meuter L; Huynh TT; Jha A; Talvacchio S; Knue M; Prodanov T; Zeiger MA; Nilubol N; Taieb D; Crona J; Shankavaram UT; Pacak K
    Endocrine; 2023 Jan; 79(1):171-179. PubMed ID: 36370152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Targeting of
    Liu Y; Pang Y; Zhu B; Uher O; Caisova V; Huynh TT; Taieb D; Hadrava Vanova K; Ghayee HK; Neuzil J; Levine M; Yang C; Pacak K
    Clin Cancer Res; 2020 Jul; 26(14):3868-3880. PubMed ID: 32152203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma.
    Calsina B; Castro-Vega LJ; Torres-Pérez R; Inglada-Pérez L; Currás-Freixes M; Roldán-Romero JM; Mancikova V; Letón R; Remacha L; Santos M; Burnichon N; Lussey-Lepoutre C; Rapizzi E; Graña O; Álvarez-Escolá C; de Cubas AA; Lanillos J; Cordero-Barreal A; Martínez-Montes ÁM; Bellucci A; Amar L; Fernandes-Rosa FL; Calatayud M; Aller J; Lamas C; Sastre-Marcos J; Canu L; Korpershoek E; Timmers HJ; Lenders JW; Beuschlein F; Fassnacht-Capeller M; Eisenhofer G; Mannelli M; Al-Shahrour F; Favier J; Rodríguez-Antona C; Cascón A; Montero-Conde C; Gimenez-Roqueplo AP; Robledo M
    Theranostics; 2019; 9(17):4946-4958. PubMed ID: 31410193
    [No Abstract]   [Full Text] [Related]  

  • 10. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative Analysis of Long Noncoding RNA (lncRNA), microRNA (miRNA) and mRNA Expression and Construction of a Competing Endogenous RNA (ceRNA) Network in Metastatic Melanoma.
    Wang LX; Wan C; Dong ZB; Wang BH; Liu HY; Li Y
    Med Sci Monit; 2019 Apr; 25():2896-2907. PubMed ID: 31004080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.
    Patterson E; Webb R; Weisbrod A; Bian B; He M; Zhang L; Holloway AK; Krishna R; Nilubol N; Pacak K; Kebebew E
    Endocr Relat Cancer; 2012 Apr; 19(2):157-66. PubMed ID: 22241719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas.
    Klein RD; Jin L; Rumilla K; Young WF; Lloyd RV
    Diagn Mol Pathol; 2008 Jun; 17(2):94-100. PubMed ID: 18382370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Analysis of Aberrantly Expressed Competitive Endogenous RNA Network and Identification of Prognostic Biomarkers in Pheochromocytoma and Paraganglioma.
    Wang Z; Li Y; Zhong Y; Wang Y; Peng M
    Onco Targets Ther; 2020; 13():11377-11395. PubMed ID: 33192072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated analysis of lncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue.
    Zhou RS; Zhang EX; Sun QF; Ye ZJ; Liu JW; Zhou DH; Tang Y
    BMC Cancer; 2019 Aug; 19(1):779. PubMed ID: 31391008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics of pheochromocytoma/paraganglioma and screening of prognostic markers.
    Lei J; Qu T; Cha L; Tian L; Qiu F; Guo W; Cao J; Sun C; Zhou B
    J Surg Oncol; 2023 Sep; 128(4):510-518. PubMed ID: 37272486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies.
    Pang Y; Liu Y; Pacak K; Yang C
    Cancers (Basel); 2019 Mar; 11(4):. PubMed ID: 30925729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
    J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.